Aptevo Therapeutics Inc. APVO
Set alert
1.35 USD +0.01 +0.75%
At close · Nov 2
1.34 -0.01 -0.74%
After hours · Nov 2, 4:00 PM ET
1.35 Day range 1.40
1.25 52-week range 28.08
- YTD
- -85.68%
- 1 year
- -95.16%
- Open
- 1.39
- Prev close
- 1.34
- Mkt cap
- 2.44M
- Vol
- 22.98K
- Avg vol
- 96.57K
- EPS
- 66.96
- P/E
- 0.02
- Div yield
- 0.00%
More statistics
- Low
- 1.35
- High
- 1.40
- Forward P/E
- -0.83
- Beta
- 5.07
- Short ratio
- 0.47
- Inst. own
- 11.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 4, 2024
- 50-d avg
- 8.69
- 200-d avg
- 31.59
- 1y target
- 21.00
5m chart
Built from the cached five-day intraday bars.
Signals (56)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 1:10 PM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 12:50 PM | 5 hours ago |
| RSI: Overbought | Nov 2, 12:20 PM | 6 hours ago |
| MACD: Sell Signal | Nov 2, 12:00 PM | 6 hours ago |
| MACD: Buy Signal | Nov 2, 11:10 AM | 7 hours ago |
| MACD: Sell Signal | Nov 2, 10:10 AM | 8 hours ago |
| SMA: Bearish | Nov 2, 10:05 AM | 8 hours ago |
| RSI: Overbought | Nov 2, 9:45 AM | 8 hours ago |
| MACD: Buy Signal | Oct 30, 3:40 PM | 3 days ago |
| RSI: Overbought | Oct 30, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| RSI: Overbought | Oct 30, 2:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:45 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:40 PM | 4 days ago |
| RSI: Overbought | Oct 29, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 4 days ago |
| RSI: Overbought | Oct 29, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 5 days ago |
| RSI: Oversold | Oct 28, 3:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:30 PM | 5 days ago |
| RSI: Oversold | Oct 28, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 6 days ago |
| RSI: Oversold | Oct 27, 3:40 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 6 days ago |
| RSI: Oversold | Oct 27, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 6 days ago |
| RSI: Oversold | Oct 27, 10:45 AM | 6 days ago |
Key statistics
- Market cap
- 2.42M
- Enterprise value
- 78.72M
- Trailing P/E
- 0.00
- Forward P/E
- -0.83
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 18.69
- EPS (TTM)
- -415.99
- Beta
- 5.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -14.68M
- Total cash
- 7.75M
- Total debt
- 4.83M
- Return on equity
- -250.96%
- Shares outstanding
- 500.33K
- Short % of float
- 7.60%
- 50-day average
- 8.69
- 200-day average
- 31.59
Analyst view
Consensus: buy
Buy
Price target (mean) 21.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 4, 2024
Expected Apr 4, 2024. Consensus EPS estimate -7.75.
Financials — quick view
APVO Revenue — quarterly 0
APVO Net income — quarterly -6.36M
APVO EPS — quarterly -5.31
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -20.65 | -17.39 | +3.26 | +15.79% |
| Aug 8, 2024 | Jun 1, 2024 | -69.93 | -60.51 | +9.42 | +13.47% |
| May 8, 2024 | Mar 1, 2024 | -510.87 | -360.51 | +150.36 | +29.43% |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -1,149.21 | -798.06 | +351.15 | +30.56% |
| Aug 10, 2023 | Jun 1, 2023 | -1,787.65 | -1,963.23 | -175.58 | -9.82% |
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aptevotherapeutics.com
News
- Aptevo Reports 10 AML Patients Advanced To Stem Cell Transplant Following Treatment With Mipletamig In Combination With Venetoclax And Azacitidine
- Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
- Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock Short Interest Rises 59.0%
- Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
- Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
- Aptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below 50 Day Moving Average – Should You Sell?
- Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
- Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on APVO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABDUN-NABI DANIEL J | Director | Conversion of Exercise of derivative security | May 30, 2024 | 277 |
| GRANT GRADY III | Director | Conversion of Exercise of derivative security | May 30, 2024 | 198 |
| HARSANYI ZSOLT | Director | Conversion of Exercise of derivative security | May 30, 2024 | 280 |
| KUNZ BARBARA LOPEZ | Director | Conversion of Exercise of derivative security | May 30, 2024 | 198 |
| KWON SOYOUNG | General Counsel | Conversion of Exercise of derivative security | Aug 7, 2024 | 801 |
| LAMOTHE JEFFREY G | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 7, 2024 | 1,166 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Hudson Bay Capital Management Lp | 1.73% | 25,285 | 122.38K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.21% | 3,017 | 14.60K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.08% | 1,181 | 5.72K | Sep 29, 2024 |
| Virtu Financial LLC | 0.08% | 1,134 | 5.49K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.07% | 989 | 4.79K | Sep 29, 2024 |
| HRT Financial LP | 0.05% | 760 | 3.68K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.08% | 1,159 | 5.61K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 56 | 271 | Sep 29, 2024 |
| Legg Mason Global Asset Mgt Tr-Franklin U.S. Small Cap Equity Fd | 0.00% | 6 | 29 | Sep 29, 2024 |